Anlon Healthcare has entered into a Share Purchase Agreement (SPA) with Apiqo Organics (formerly known as M/s Apple Life Science, a partnership firm) (Target Company) for acquisition of 67.48% shareholding of the Target Company from 3 shareholders of such Target Company, in accordance with and subject to the terms and conditions as set out in the SPA.
Pursuant to the terms of the SPA and upon fulfilment of the conditions precedent contained in the SPA, Purchaser being the Company will acquire management and control of the Target Company, and upon completion of such acquisition, the Target Company will become Subsidiary of the Company.
The proposed strategic acquisition of the Target Company significantly enhances the Company’s vertical integration, secures critical supply of high-quality intermediates, increases additional 700 to 800 MT annual manufacturing capacity for advanced pharmaceutical intermediates, and strengthens the ability of the Company to deliver reliable, cost-effective solutions to its global pharmaceutical partners. The proposed acquisition not only secures supply of critical materials for the Company but also positions it as a more agile, cost-competitive, and reliable partner for innovator and generic pharmaceutical companies worldwide.
Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1903.00 |
| Dr. Reddys Labs. | 1353.75 |
| Cipla | 1452.35 |
| Zydus Lifesciences | 1152.90 |
| Lupin | 2489.85 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: